Longitude Capital is a venture capital firm that specializes in investments in biotechnology, medical technology, and health solutions. Founded in 2006 and based in Menlo Park, California, with an additional office in Boston, Massachusetts, the firm has raised over $2 billion across six funds and manages approximately $1.7 billion in assets. The firm focuses on improving clinical outcomes and enhancing patient quality of life while reducing healthcare costs. Longitude Capital invests in both privately held and publicly traded companies, utilizing various investment structures. Beyond providing capital, the firm offers strategic guidance and mentorship to its portfolio companies, assisting them in achieving key objectives and building strong teams. With a team that has over 200 years of combined experience in life sciences, Longitude Capital has made over 90 new investments and 150 follow-on investments, leveraging a broad industry network and proprietary research capabilities to identify emerging opportunities in healthcare.
We're tracking Longitude Capital's market expansion
How Longitude Capital's international expansion compares to its competitors
Longitude CapitalYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Longitude CapitalYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Haisco Pharmaceutical licenses global rights for HSK39004, a dual PDE3/4 inhibitor for COPD, to AirNexis for up to $1.063 billion, marking a breakthrough in Chinese respiratory innovation.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Longitude Capital's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
